Autopsy report · NCT00136591

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

“An arm closed due to lack of efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 4 months before it stopped.
• 87 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Lymphoma Study Association

Sponsor type

University, hospital or other

Conditions

Follicular Lymphoma

Interventions

Bortezomib; Bortezomib

Participants

87

Sites

4

Countries

Belgium, France

Trials that died the same way

• Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to Fluoropyrimidines
  “The study stopped due to a death in the arm control” (68% match in meaning)
• Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
  “Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.